Cite

    Michael Gray et al.. “Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.” Breast cancer research, vol. 18, no. 1, 2016, pp. 1–14. http://access.bl.uk/ark:/81055/vdc_100080455100.0x000063